Delcath Systems (DCTH) announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating Hepzato in combination with standard of care treatment for liver-dominant metastatic colorectal cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Updates Bylaws for Governance Efficiency
- Delcath Systems’ HEPZATO Drives Strong Growth and Expansion, Justifying Buy Rating
- Delcath Systems price target raised to $31 from $29 at H.C. Wainwright
- Delcath Systems Reports Strong Q2 2025 Results
- Delcath Systems Reports Strong Q2 Growth Amid Challenges